Literature DB >> 26800490

Chronic lymphocytic leukemia: Time to go past genomics?

Damien Roos-Weil1,2,3,4, Florence Nguyen-Khac5,6,7, Olivier A Bernard1,2,3,4.   

Abstract

Recent advances in massively parallel sequencing technologies have provided a detailed picture of the mutational landscape in CLL and underscored the vast degree of interpatient and intratumor heterogeneities. These studies have led to the characterization of novel putative driver genes and recurrently affected biological pathways, and to the modeling of CLL clonal evolution. We herein review selected aspects including recent advances in the biology of CLL and present cellular and biological processes involved in the development of CLL and potentially other mature B-cell lymphoproliferative neoplasms.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26800490     DOI： 10.1002/ajh.24301

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  7 in total

1.  GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death.

Authors:  Juliana Carvalho Alves-Silva; Juliana Lott de Carvalho; Doralina Amaral Rabello; Teresa Raquel Tavares Serejo; Eduardo Magalhaes Rego; Francisco Assis Rocha Neves; Antonio Roberto Lucena-Araujo; Fábio Pittella-Silva; Felipe Saldanha-Araujo
Journal:  Invest New Drugs       Date:  2018-05-31       Impact factor: 3.850

2.  Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.

Authors:  Luma Dayane de Carvalho Filiú-Braga; Teresa Raquel Tavares Serejo; Antonio Roberto Lucena-Araujo; Francisco Assis Rocha Neves; Juliana Lott de Carvalho; Eduardo Magalhaes Rego; Felipe Saldanha-Araujo
Journal:  Med Oncol       Date:  2018-11-13       Impact factor: 3.064

3.  B-cell tumor development in Tet2-deficient mice.

Authors:  Enguerran Mouly; Hussein Ghamlouch; Veronique Della-Valle; Laurianne Scourzic; Cyril Quivoron; Damien Roos-Weil; Patrycja Pawlikowska; Véronique Saada; M'Boyba K Diop; Cécile K Lopez; Michaela Fontenay; Philippe Dessen; Ivo P Touw; Thomas Mercher; Said Aoufouchi; Olivier A Bernard
Journal:  Blood Adv       Date:  2018-03-27

4.  Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.

Authors:  Selcen Öztürk; Yashna Paul; Saira Afzal; Irene Gil-Farina; Anna Jauch; Peter-Martin Bruch; Verena Kalter; Bola Hanna; Lavinia Arseni; Philipp M Roessner; Manfred Schmidt; Stephan Stilgenbauer; Sascha Dietrich; Peter Lichter; Marc Zapatka; Martina Seiffert
Journal:  Leukemia       Date:  2021-08-20       Impact factor: 11.528

Review 5.  NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.

Authors:  Emanuela Rosati; Stefano Baldoni; Filomena De Falco; Beatrice Del Papa; Erica Dorillo; Chiara Rompietti; Elisa Albi; Franca Falzetti; Mauro Di Ianni; Paolo Sportoletti
Journal:  Front Oncol       Date:  2018-06-27       Impact factor: 6.244

Review 6.  Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia.

Authors:  Sandra Kurtin; Ali McBride
Journal:  J Adv Pract Oncol       Date:  2017-07-01

Review 7.  Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets.

Authors:  Giacomo Andreani; Giovanna Carrà; Marcello Francesco Lingua; Beatrice Maffeo; Mara Brancaccio; Riccardo Taulli; Alessandro Morotti
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.